Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Actavis Stories

2014-01-08 16:26:48

DUBLIN, Jan. 8, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis(®). Actavis intends to launch the product immediately. As a "first applicant" to submit a substantially complete ANDA, Actavis is eligible for 180 days of...

2014-01-06 16:27:57

DUBLIN, Jan. 6, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 31, 2014 in New York. The meeting will begin at 8:00 a.m. EST and will be webcast simultaneously. The meeting will be hosted by Actavis' executive leadership team and will provide an overview of executional results in 2013, initiatives to drive long-term growth and an in-depth look at the company following...

2013-12-24 08:24:08

DUBLIN, Dec. 24, 2013 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that its subsidiary, Warner Chilcott Company LLC, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Ethinyl Estradiol and Etonogestrel Vaginal Ring, 0.015 mg/24 hour and 0.12 mg/24 hour. Actavis' ANDA product is a generic version of Merck & Co.'s NuvaRing(®), which is an estrogen/progestin combination hormonal...

2013-12-24 08:24:01

DUBLIN, Dec. 24, 2013 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the Company's subsidiary has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy. The Company stated that it intends to work closely with the FDA to address the items raised in the complete response...

2013-12-20 12:24:05

DUBLIN, Dec. 20, 2013 /PRNewswire/ -- Actavis plc (NYSE:ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Chairman and Chief Executive Officer, will provide an overview and update of the Company's business at the 32(nd) Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014 at 7:30 am PST (10:30 am EST) at the Westin St. Francis Hotel, San Francisco, California. To access the webcast, go to Actavis' Investor Relations Web site at...

2013-12-17 12:22:47

New Report from Decision Resources Explores Near-Term Opportunities in the U.S. Generic Drug Market BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that between 2013 and 2020, 40 blockbuster brands will lose patent exclusivity in the United States. According to the new Strategic Insights report entitled Indian Generics Manufacturers Penetrate U.S. Generics...

2013-12-16 16:25:58

WARSAW, Ind., Dec. 16, 2013 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal care, today announced that Paul Bisaro, Chairman, President and Chief Executive Officer of Actavis plc (NYSE: ACT), has been appointed to its Board of Directors. Mr. Bisaro has served as President and Chief Executive Officer and a member of the board of directors of Actavis (formerly Watson Pharmaceuticals, Inc.), a global, integrated specialty pharmaceutical...

2013-12-11 08:31:39

Pending US FDA Approval, Expected Product Launch with Actavis in Second Half of 2014 SYDNEY and BEDMINSTER, N.J., Dec. 11, 2013 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Food and Drug Administration (FDA) has established 25 May 2014 as the new Prescription Drug User Fee Act (PDUFA) date for action on the Company's refiled New Drug Application (NDA) for immediate release MOXDUO. The FDA will schedule an Advisory Committee...

2013-12-11 08:30:36

DUBLIN, Dec. 11, 2013 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading specialty pharmaceutical company, today announced that it its subsidiary, Warner Chilcott Company, LLC, has entered into an agreement in principle with Zydus Pharmaceuticals USA Inc. and Cadila Healthcare Limited to settle all outstanding patent litigation related to Zydus' generic version of Asacol(®) HD (mesalamine) delayed-release tablets. The agreement remains subject to preparation and execution of...

2013-12-10 23:20:12

Reportbuyer.com just published a new market research report: Biosimilar Opportunities in an Evolving Market. London (PRWEB) December 10, 2013 Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two...